- Home
- FBYD vs ZNTL Comparison
FBYD vs ZNTL Comparison
Compare FBYD & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBYD | ZNTL |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.3M | 289.0M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FBYD | ZNTL |
|---|---|---|
| Price | $7.41 | $2.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 119.9K | ★ 832.9K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $14,896,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $168.75 | ★ N/A |
| Revenue Growth | ★ 120.85 | N/A |
| 52 Week Low | $3.71 | $1.21 |
| 52 Week High | $29.02 | $6.95 |
Technical Indicators
Market Signals| Indicator | FBYD | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 22.91 |
| Support Level | $5.80 | $2.09 |
| Resistance Level | $8.08 | $4.06 |
| Average True Range (ATR) | 0.75 | 0.21 |
| MACD | 0.13 | -0.06 |
| Stochastic Oscillator | 52.85 | 4.14 |
Price Performance
Historical ComparisonAbout FBYD Falcon's Beyond Global Inc.
Falcons Beyond Global Inc is a visionary entertainment and technology enterprise. The group designs, develops, engineers, delivers, and commercializes immersive physical and digital experiences for brands, developers, and destination operators world-wide, as well as for its own portfolio of entertainment and technology concepts. The Company has five operating segments: Falcon's Creative Group, Destinations Operations, PDP, Falcon's Beyond Brands, and Falcon's Attractions. It earns the majority of the revenue from Falcon's Creative Group segment.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.